Death of Teenage Girl in Japan Linked to Pfizer mRNA COVID Shot
A 14-year-old girl died in Japan on Aug. 12, 2022, two days after receiving a third dose of Pfizer/BioNTech’s Comirnaty messenger RNA (mRNA) COVID-19 shot. The child reportedly developed a fever of 100.22 °F a day after the shot. That evening, she experienced breathing problems but still managed to fall asleep.1 2 3
According to a case report by researchers at Tokushima University Graduate School and published in the medical journal Legal Medicine on Mar. 20, 2023:
The following morning, her mother noticed that she was not breathing and had a pale appearance, and she immediately called an ambulance. The patient was in cardiopulmonary arrest when the ambulance crew arrived at their house and attempts to administer advanced life support were unsuccessful.1 2 3
The case report states that the child was diagnosed with “vaccination pneumonia, myopericarditis, hepatitis, nephritis, gastroenteritis, cystitis and myositis.”1 2 3 Autopsy findings showed:
congestive edema of the lungs, T-cell lymphocytic and macrophage infiltration in the lungs, pericardium and myocardium of the left atria and left ventricle [of the heart], liver, kidneys, stomach, duodenum, bladder, and diaphragm.3
The cause of death was determined to be “vaccine-related myopericarditis.” The myopericarditis (inflammation of both the heart muscle and outer lining of the heart known as the pericardium), in turn, “led to severe arrhythmias and progressive heart failure.”1 2 3
Since the COVID shots (beginning with Comirnaty) were introduced in Japan in February 2021, that country’s government has received more than 2,000 reports of deaths related to the shots. Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved payments for at least 850 people who suffered adverse reactions to COVID shots. As of July 2022, the ministry had received applications for vaccine-related compensation from 3,680 people.2 4 5
Myocarditis and Pericarditis After COVID Vaccination Increasingly Reported in U.S.
In the United States, reports of post-COVID vaccination myocarditis and pericarditis have been on the rise since a case report by a team of researchers led by Elisabeth Albert MD was published in Radiology Case Reports in August 2021. That case involved a 24-year-old man who was hospitalized for “acute substernal chest pain” four days after his second dose of Moderna/NIAID’s Spikevax mRNA COVID shot. The authors of the report said that their findings “raises concern that myocarditis is a rare side effect of COVID-19 vaccine.”3 6
The Tokushima University case report cited a survey conducted by the U.S. military which identified 23 cases of myocarditis per 2,800,000 persons with a mean age of 25 years. It also cited reports by U.S. hospitals of 20 cases of myocarditis per 2,000,287 persons and 37 cases of pericarditis per 2,000,287 persons, with a mean age of onset of 36 years for myocarditis and 59 years for pericarditis.3
Additionally, a Nordic cohort study involving 23 million people found that myocarditis occurred in 1,077 out of 23,122,522 people and pericarditis in 1,149 out of 23,122,522 people. Both myocarditis and pericarditis were more common in young men ranging in ages from 16 to 24 years.3 7
Heart inflammation most commonly developed after the second COVID vaccination. The Nordic study was published in the journal JAMA Cardiology in June 2022.7
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
Click here to view References:
No comments:
Post a Comment